 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug ERYTHROMYCIN: DO-NOT-KNOW[0m

[34mThe question asked was whether erythromycin increases or decreases the risk of hospitalization. I attempted to obtain this information by sending a query to FDAHandler. However, without a response [0m
[34mfrom FDAHandler, I cannot provide a reliable answer based on FDA label data. Therefore, the answer is DO-NOT-KNOW.[0m
[1;34m2[0m[34m. Drug ERYTHROMYCIN ETHYLSUCCINATE: DO-NOT-KNOW[0m

[34mThe FDA label for ERYTHROMYCIN ETHYLSUCCINATE does not specifically address the risk of hospitalization. While it does mention precautions and potential adverse effects that could lead to serious [0m
[34mconditions if not managed properly, such as infantile hypertrophic pyloric stenosis [0m[1;34m([0m[34mIHPS[0m[1;34m)[0m[34m requiring surgical intervention in newborns and the risk of developing superinfection with prolonged or [0m
[34mrepeated use, there is no direct statement about the overall risk of hospitalization due to the drug. Therefore, it is not possible to definitively say whether ERYTHROMYCIN ETHYLSUCCINATE increases or[0m
[34mdecreases the risk of hospitalization. The degree of risk would depend on individual patient factors and the management of any adverse effects that may arise.[0m
[1;34m3[0m[34m. Drug ERYTHROMYCIN: I apologize for the confusion, but I need to clarify that I cannot provide an answer to the question of whether erythromycin increases or decreases the risk of hospitalization [0m
[34mwithout specific data from the FDA label. The FDA label data does not specify the answer to this question, and therefore, my final answer is DO-NOT-KNOW. [0m

[34m DO-NOT-KNOW[0m
[34m                ---------[0m
[34m                Does the erythromycin category of drugs increase the risk of[0m
[34m                hospitalization, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the erythromycin category of drugs increase the risk of hospitalization, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The passages provided do not contain specific information regarding the effect of erythromycin or its derivatives on the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"Passage 1 indicates that without a response from FDAHandler, the effect of erythromycin on hospitalization risk is unknown."[0m[32m,[0m
[32m      [0m[32m"Passage 2 mentions potential adverse effects of erythromycin ethylsuccinate that could lead to serious conditions but does not directly link the drug to an increased risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"Passage 3 reiterates the lack of specific data from the FDA label regarding the impact of erythromycin on hospitalization risk."[0m[32m,[0m
[32m      [0m[32m"Given the absence of clear evidence or data, it is not possible to determine whether the erythromycin category of drugs has an effect on the risk of hospitalization."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect of the erythromycin category of drugs on the risk of hospitalization based on the information provided."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the erythromycin category of drugs increase the risk of hospitalization, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The passages provided do not contain specific information regarding the effect of erythromycin or its derivatives on the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"Passage 1 indicates that without a response from FDAHandler, the effect of erythromycin on hospitalization risk is unknown."[0m[34m,[0m
[34m      [0m[34m"Passage 2 mentions potential adverse effects of erythromycin ethylsuccinate that could lead to serious conditions but does not directly link the drug to an increased risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"Passage 3 reiterates the lack of specific data from the FDA label regarding the impact of erythromycin on hospitalization risk."[0m[34m,[0m
[34m      [0m[34m"Given the absence of clear evidence or data, it is not possible to determine whether the erythromycin category of drugs has an effect on the risk of hospitalization."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect of the erythromycin category of drugs on the risk of hospitalization based on the information provided."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the erythromycin category of drugs increase the risk of hospitalization, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The passages provided do not contain specific information regarding the effect of erythromycin or its derivatives on the risk of hospitalization.[0m
[1;31m2[0m[31m. Passage [0m[1;31m1[0m[31m indicates that without a response from FDAHandler, the effect of erythromycin on hospitalization risk is unknown.[0m
[1;31m3[0m[31m. Passage [0m[1;31m2[0m[31m mentions potential adverse effects of erythromycin ethylsuccinate that could lead to serious conditions but does not directly link the drug to an increased risk of hospitalization.[0m
[1;31m4[0m[31m. Passage [0m[1;31m3[0m[31m reiterates the lack of specific data from the FDA label regarding the impact of erythromycin on hospitalization risk.[0m
[1;31m5[0m[31m. Given the absence of clear evidence or data, it is not possible to determine whether the erythromycin category of drugs has an effect on the risk of hospitalization.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect of the erythromycin category of drugs on the risk of hospitalization based on the information provided.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is flawed because it does not follow the instruction that the absence of information related to a condition in the FDA data for all drugs in a category should [0m
[32mbe enough to conclude that there is no effect for that drug. The reasoning states that the effect is unknown due to the lack of specific information, which contradicts the instruction. The correct [0m
[32mconclusion should be that there is no effect on the risk of hospitalization from the erythromycin category of drugs, given the absence of evidence linking the drug category to the risk of the [0m
[32mcondition."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is flawed because it does not follow the instruction that the absence of information related to a condition in the FDA data for all drugs in a category should [0m
[34mbe enough to conclude that there is no effect for that drug. The reasoning states that the effect is unknown due to the lack of specific information, which contradicts the instruction. The correct [0m
[34mconclusion should be that there is no effect on the risk of hospitalization from the erythromycin category of drugs, given the absence of evidence linking the drug category to the risk of the [0m
[34mcondition."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is flawed because it does not follow the instruction that the absence of information related to a condition in the FDA data for all drugs in a category should [0m
[31mbe enough to conclude that there is no effect for that drug. The reasoning states that the effect is unknown due to the lack of specific information, which contradicts the instruction. The correct [0m
[31mconclusion should be that there is no effect on the risk of hospitalization from the erythromycin category of drugs, given the absence of evidence linking the drug category to the risk of the [0m
[31mcondition.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the erythromycin category of drugs increase the risk of hospitalization, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The passages provided do not contain specific information regarding the effect of erythromycin or its derivatives on the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"According to the instruction, the absence of information related to a condition in the FDA data for all drugs in a category should be interpreted as indicating that there is no effect of the [0m
[32mdrug on that condition."[0m[32m,[0m
[32m      [0m[32m"Passages 1 and 3 explicitly state that the effect of erythromycin on hospitalization risk is unknown due to the lack of specific data from the FDA label."[0m[32m,[0m
[32m      [0m[32m"Passage 2, while mentioning potential adverse effects of erythromycin ethylsuccinate, does not establish a direct link to hospitalization risk and thus does not provide evidence of an effect."[0m[32m,[0m
[32m      [0m[32m"Given the absence of evidence linking erythromycin or its derivatives to an increased or decreased risk of hospitalization, and following the instruction provided, the conclusion should be that[0m
[32mthere is no effect on the risk of hospitalization from the erythromycin category of drugs."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect of the erythromycin category of drugs on the risk of hospitalization based on the absence of evidence in the FDA data."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the erythromycin category of drugs increase the risk of hospitalization, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The passages provided do not contain specific information regarding the effect of erythromycin or its derivatives on the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"According to the instruction, the absence of information related to a condition in the FDA data for all drugs in a category should be interpreted as indicating that there is no effect of the [0m
[34mdrug on that condition."[0m[34m,[0m
[34m      [0m[34m"Passages 1 and 3 explicitly state that the effect of erythromycin on hospitalization risk is unknown due to the lack of specific data from the FDA label."[0m[34m,[0m
[34m      [0m[34m"Passage 2, while mentioning potential adverse effects of erythromycin ethylsuccinate, does not establish a direct link to hospitalization risk and thus does not provide evidence of an effect."[0m[34m,[0m
[34m      [0m[34m"Given the absence of evidence linking erythromycin or its derivatives to an increased or decreased risk of hospitalization, and following the instruction provided, the conclusion should be that[0m
[34mthere is no effect on the risk of hospitalization from the erythromycin category of drugs."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect of the erythromycin category of drugs on the risk of hospitalization based on the absence of evidence in the FDA data."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the erythromycin category of drugs increase the risk of hospitalization, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The passages provided do not contain specific information regarding the effect of erythromycin or its derivatives on the risk of hospitalization.[0m
[1;31m2[0m[31m. According to the instruction, the absence of information related to a condition in the FDA data for all drugs in a category should be interpreted as indicating that there is no effect of the drug [0m
[31mon that condition.[0m
[1;31m3[0m[31m. Passages [0m[1;31m1[0m[31m and [0m[1;31m3[0m[31m explicitly state that the effect of erythromycin on hospitalization risk is unknown due to the lack of specific data from the FDA label.[0m
[1;31m4[0m[31m. Passage [0m[1;31m2[0m[31m, while mentioning potential adverse effects of erythromycin ethylsuccinate, does not establish a direct link to hospitalization risk and thus does not provide evidence of an effect.[0m
[1;31m5[0m[31m. Given the absence of evidence linking erythromycin or its derivatives to an increased or decreased risk of hospitalization, and following the instruction provided, the conclusion should be that [0m
[31mthere is no effect on the risk of hospitalization from the erythromycin category of drugs.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect of the erythromycin category of drugs on the risk of hospitalization based on the absence of evidence in the FDA data.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"no-effect"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.9[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"none"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"Based on the provided passages, there is no specific information or evidence from the FDA data that links the erythromycin category of drugs to an increased or decreased risk of [0m
[32mhospitalization. The absence of such information is interpreted as indicating no effect on hospitalization risk."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-hospitalization-erythromycin[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
